RxDoctor Payments Data

Garrett Bohrnstedt, DO

Dermatology · Lynchburg, VANPI 1699904052

Payments from drug & device makers

$8,355in general payments, 2019–2025

Across 406 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$1K
  • Novartis$642
  • Sanofi$640
  • Pfizer$559
  • Sun Pharmaceutical Industries Inc.$463
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$7,58191%
  • Education$7749%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,355 in reported general payments places this provider in the 75th percentile of 396 dermatology providers in Virginia.

See all dermatology providers in Virginia

Medicare billing

Part B allowed, 2024
$374,270
Medicare patients
1,244
Services billed
5,816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TremfyaGuselkumab18$240,950
Dupixent PenDupilumab61$238,246
Skyrizi PenRisankizumab-Rzaa11$224,855
Humira(Cf)Adalimumab13$164,944
Clobetasol Propionate289$11,079
Tacrolimus32$5,586
Clindamycin Phosphate43$2,418
Doxycycline Hyclate42$1,778
Fluocinonide21$1,337
Doxycycline Monohydrate49$1,332
Triamcinolone Acetonide197$1,233
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc28$1,169
Metronidazole23$943
Halobetasol Propionate12$918
MethotrexateMethotrexate Sodium16$756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$1,269$240,95018 claims
AbbVieHumira(Cf)$2,728$164,94413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 396 dermatology providers in Virginia.

Other dermatology in Lynchburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →